Additionally, the IDH1/2 mutated gliomas have also shown sensitivity to PARPi and as a result, several of the current clinical trials are aimed at evaluating PARPi sensitization of gliomas to temozolomide or combinatorial drug treatments (including PARPi) using either MGMT promoter methylation or IDH1/2 mutation status to stratify patients that can benefit from these combination therapies [25]. Here, IDH1 is linked to central nervous system cancer.